Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades

Table 2 Clinical studies (N) per indication over the past two decades

Indications	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
CARD	7	12	26	33	48	74	56	68	59	43	52	42	20	42	31	17	22	14	11	11	9
DERM	1	1	5	9	18	10	8	15	17	13	19	19	16	24	19	26	30	19	36	40	22
HAEM	1	3	11	4	16	16	19	21	33	25	15	10	11	10	15	8	15	9	11	7	4
HORM	1	2	0	1	2	1	3	1	3	1	3	0	2	2	2	1	0	1	0	0	2
INFEC	9	15	27	46	45	77	114	108	95	110	94	99	92	75	91	84	52	34	40	26	31
META	14	36	69	74	98	101	154	123	138	137	164	127	132	112	101	67	85	82	73	63	43
MUSCO	2	6	10	20	35	28	29	32	25	23	30	15	18	24	21	18	17	10	10	11	5
NEURO	15	25	52	88	136	110	154	161	150	132	128	106	78	62	61	52	36	34	54	37	45
ONCIM	20	25	56	84	96	147	192	196	200	207	193	203	159	150	153	115	129	102	112	94	87
PARA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESP	5	7	31	26	38	54	52	76	69	65	83	74	85	65	62	49	39	45	17	17	10
SENS	3	3	10	13	17	21	17	19	32	17	29	16	15	14	19	10	7	3	4	5	4
URO	7	2	8	29	27	37	20	29	28	31	23	25	15	14	10	13	10	10	9	5	7
VAR	3	2	6	8	8	12	16	11	34	20	13	14	16	10	9	14	3	8	10	3	5

ISSN: 2052-3211